Alexion Pharmaceuticals, Inc. has announced research findings showing that its anti-C5 monoclonal antibody can be effectively delivered to the lungs to substantially block airway inflammation and ...
Alexion Pharmaceuticals, Inc has announced that positive results from one of the two large phase 3 studies of ALXN1210, the company's investigational long-acting C5 complement inhibitor, in patients ...
Alexion Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for approval of ALXN1210, the company’s ...
Orphan drugmakers focus on developing drugs for rare diseases, but unfortunately many companies in this space never become profitable. Of those that do, few are able to succeed like Alexion ...
(Alliance News) - German bank Berenberg talked up AstraZeneca PLC's Alexion Pharmaceuticals, believing it is still in good shape despite some competitors entering the market. Berenberg, after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results